Table 2 Clinical significance of MIR22HG in various human tumors

thyroid carcinoma

Low MIR22HG expression was related to tumor size (P = 0.015), TNM stage (P = 0.022) and poor overall survival (P = 0.030).

[21]

Low MIR22HG expression was significantly related to the lymph node metastasis status (P < 0.01), the residual tumor status (P < 0.05), N stage (P < 0.05), tumor grade (P < 0.001) and T stage (P < 0.001) while high MIR22HG expression was significantly correlated with the disease recurrence rate (P < 0.01), overall survival time (P = 0.0665) and disease-free survival time (P < 0.05) in TC by analyzing TCGA, the GSE29265, GSE33630, and GSE55091 public datasets.

[22]

hepatocellular carcinoma

Low MIR22HG expression was associated with short overall survival (P = 0.045) and poor disease-free survival (P = 0.036).

[23]

Patients with high MIR22HG expression exhibited better overall survival (145-patient cohort: P = 0.001; TCGA cohort: P = 0.015) and disease-free survival (145-patient cohort: P = 0.042; TCGA cohort: P = 0.003) than those with low MIR22HG expression.

[24]

cholangiocarcinoma

Low MIR22HG expression was positively correlated with advanced clinical stage (TNM) (P = 0.039), large tumor size (P = 0.002), lymph node metastasis (P = 0.0001), and poor overall survival (P = 0.020).

[26]

colorectal

cancer

Low MIR22HG expression was significantly associated

with poor overall survival (P = 0.0008) and disease-free survival (P = 0.0009).

[27]

gastric cancer

Low MIR22HG expression indicated a low 5-year overall survival rate (P < 0.05).

[28]

non-small cell lung cancer

Low MIR22HG expression was correlated with poor patient survival (P = 0.003) in an independent UM cohort including 101 LUAD tissues and 27 normal lung tissues.

[30]

glioblastoma

High MIR22HG expression was associated with patient age (P < 0.001), Karnofsky Performance Status score (P < 0.001), advanced tumor grade and poor overall survival (P < 0.05).

[31]